286 related articles for article (PubMed ID: 34398977)
1. De novo generalized pustular psoriasis following Oxford-AstraZeneca COVID-19 vaccine.
Elamin S; Hinds F; Tolland J
Clin Exp Dermatol; 2022 Jan; 47(1):153-155. PubMed ID: 34398977
[TBL] [Abstract][Full Text] [Related]
2. Generalized bullous fixed drug eruption after Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccination.
Wantavornprasert K; Noppakun N; Klaewsongkram J; Rerknimitr P
Clin Exp Dermatol; 2022 Feb; 47(2):428-432. PubMed ID: 34482558
[No Abstract] [Full Text] [Related]
3. Symmetrical drug-related intertriginous and flexural exanthema like eruption associated with COVID-19 vaccination.
Lim PN; Wylie G
Clin Exp Dermatol; 2022 Jan; 47(1):175-176. PubMed ID: 34399001
[TBL] [Abstract][Full Text] [Related]
4. A Case of
Chhabra N; George A
Curr Drug Saf; 2023 Apr; 18(4):584-588. PubMed ID: 35702789
[TBL] [Abstract][Full Text] [Related]
5. Comment on 'De novo generalized pustular psoriasis following Oxford-AstraZeneca COVID-19 vaccine': possible role for Type I interferons.
Awada B; Abdullah L; Kurban M; Abbas O
Clin Exp Dermatol; 2022 Feb; 47(2):443. PubMed ID: 34551138
[No Abstract] [Full Text] [Related]
6. Another case of generalized bullous fixed drug eruption following an adenoviral vector-based COVID-19 vaccine (ChAdOx1 nCov-19).
Ben Salem C; Khelif A; Sahnoun D; Ghariani N; Sriha B; Denguezli M
J Eur Acad Dermatol Venereol; 2022 Jul; 36(7):e516-e517. PubMed ID: 35274363
[No Abstract] [Full Text] [Related]
7. Relapsed ANCA associated vasculitis following Oxford AstraZeneca ChAdOx1-S COVID-19 vaccination: A case series of two patients.
David R; Hanna P; Lee K; Ritchie A
Nephrology (Carlton); 2022 Jan; 27(1):109-110. PubMed ID: 34755433
[No Abstract] [Full Text] [Related]
8. Cutaneous Lymphocytic Vasculitis After Administration of the Second Dose of AZD1222 (Oxford-AstraZeneca) Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination: Casuality or Causality?
Ungari M; Pezzarossa E
Am J Dermatopathol; 2022 Jan; 44(1):80-82. PubMed ID: 34726187
[No Abstract] [Full Text] [Related]
9. Phenotypic spectrum of serious cutaneous-only adverse event following immunization with COVID-19 vaccines: a multicentre case series and literature review.
Balogun M; Millette D; Yip V; Chan SA; Lee P; Gamal N; Hashim N; Phillips D; Walsh M; Trehan P; Hanna-Bashara L; Abdullah A; Wernham A; Tso S
Clin Exp Dermatol; 2022 Mar; 47(3):614-616. PubMed ID: 34748655
[No Abstract] [Full Text] [Related]
10. Isolated thrombosis after COVID-19 vaccination: case series.
Al-Ahmad M; Al Rasheed M; Altourah L; Rodriguez-Bouza T; Shalaby N
Int J Hematol; 2022 Feb; 115(2):153-157. PubMed ID: 34993889
[TBL] [Abstract][Full Text] [Related]
11. Onset/flare of psoriasis following the ChAdOx1 nCoV-19 Corona virus vaccine (Oxford-AstraZeneca/Covishield): Report of two cases.
Nagrani P; Jindal R; Goyal D
Dermatol Ther; 2021 Sep; 34(5):e15085. PubMed ID: 34350668
[No Abstract] [Full Text] [Related]
12. Bullous Sweet syndrome following SARS-CoV-2 Oxford AstraZeneca vaccine.
Žagar T; Hlača N; Brajac I; Prpić-Massari L; Peternel S; Kaštelan M
Br J Dermatol; 2022 Mar; 186(3):e110. PubMed ID: 34817862
[No Abstract] [Full Text] [Related]
13. Clinical Variant of Guillain-Barre Syndrome With Prominent Facial Diplegia After AstraZeneca Coronavirus Disease 2019 Vaccine.
Badoiu A; Moranne O; Coudray S; Ion IM
J Clin Neuromuscul Dis; 2021 Dec; 23(2):115-116. PubMed ID: 34808658
[No Abstract] [Full Text] [Related]
14. Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2.
Pattni K; Hungerford D; Adams S; Buchan I; Cheyne CP; García-Fiñana M; Hall I; Hughes DM; Overton CE; Zhang X; Sharkey KJ
BMC Infect Dis; 2022 Mar; 22(1):270. PubMed ID: 35307024
[TBL] [Abstract][Full Text] [Related]
15. Inverse lichen planus post Oxford-AstraZeneca COVID-19 vaccine.
Awada B; Abdullah L; Kurban M; Abbas O
J Cosmet Dermatol; 2022 Mar; 21(3):883-885. PubMed ID: 34997985
[No Abstract] [Full Text] [Related]
16. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous thrombosis associated with skin necrosis following Oxford-AstraZeneca COVID-19 vaccination.
Ramessur R; Saffar N; Czako B; Agarwal A; Batta K
Clin Exp Dermatol; 2021 Dec; 46(8):1610-1612. PubMed ID: 34189756
[No Abstract] [Full Text] [Related]
18. Coincidental Onset of Ocular Myasthenia Gravis Following ChAdOx1 n-CoV-19 Vaccine against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Galassi G; Rispoli V; Iori E; Ariatti A; Marchioni A
Isr Med Assoc J; 2022 Jan; 24(1):9-10. PubMed ID: 35077038
[TBL] [Abstract][Full Text] [Related]
19. Self-reported side effects of the Oxford AstraZeneca COVID-19 vaccine among healthcare workers in Ethiopia, Africa: A cross-sectional study.
Yesuf EA; Riad A; Sofi-Mahmudi A; Sudhakar M; Mekonnen A; Endalkachew S; Mama F; Muhidin S; Ayele B; Yahya M; Usman A; Abafita J; Klugar M
Front Public Health; 2022; 10():937794. PubMed ID: 35928493
[TBL] [Abstract][Full Text] [Related]
20. Oxford-AstraZeneca ChAdOx1 COVID-19 Vaccine Does Not Alter Platelet Aggregation.
Limami Y; Khalki L; Zaid N; Khyatti M; Turk JE; Ammara M; Mtairag EM; Oudghiri M; Naya A; Taberkant M; Zaid Y
Semin Thromb Hemost; 2022 Feb; 48(1):109-111. PubMed ID: 33971677
[No Abstract] [Full Text] [Related]
[Next] [New Search]
